Skip to main content

Commitment to PAH

A commitment to educate, enable, and inspire

PAH management and treatment have come a long way in the past few decades. Advances in care have given patients the hope to live better with PAH.

That’s powerful.

United Therapeutics harnesses that power in everything we do. Founded by the parents of a daughter diagnosed with PAH, we understand what it’s like to be in an exam room when a patient is told they have PAH, and we know the challenges of living with this complex, rare disease.

We are committed to improving the lives of patients with PAH—it’s a core part of our identity. That’s why United Therapeutics sponsors the PAH Initiative. The PAH Initiative seeks to further our commitment to the PAH community by

  • Educating patients with information that improves understanding of a complex, rare disease
  • Enabling healthcare professionals by providing information and resources designed to help them transform knowledge into patient care
  • Inspiring the PAH community to improve the lives of people impacted by PAH

Going to CHEST?

Can first-year treatment decisions really change PAH outcomes?

Hear experts explore the data

The Clinical Challenge: How Important Is the First Year of PAH Therapy?

Monday, October 19, 2026

2:30 ᴘᴍ–3:15 ᴘᴍ

Phoenix Convention Center

Learning Theater 3

Hear 4 PAH experts explore key considerations in patient care today:

  • Why low risk matters
  • How early action can help improve outcomes
  • How frequent risk assessments and right heart evaluations can inform treatment decisions